Jefferies raised its price target for Axsome Therapeutics (NASDAQ: AXSM) to $380 from $275. The firm maintained its Buy rating, noting significant upside from current trading levels.
Analysts project peak sales for the drug Auvelity could exceed $6 billion. This forecast includes treatments for major depressive disorder and Alzheimer's disease agitation. The estimate represents a substantial increase over the current revenue run rate.
Jefferies identifies additional valuation upside from Axsome's pipeline of more than 10 late-stage indications. This update follows the company's Q1 2026 financial results. Axsome also recently resolved patent litigation for its product SUNOSI.